Radiotherapy & Oncology
Volume 81, Issue 2 , Pages 163-167 , November 2006

Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC)

  • Atif J. Khan

      Affiliations

    • Department of Radiation Oncology,
    • ,
  • Par S. Mehta

      Affiliations

    • Department of Radiation Oncology,
    • ,
  • Thomas W. Zusag

      Affiliations

    • Department of Radiation Oncology,
    • ,
  • Philip D. Bonomi

      Affiliations

    • Department of Internal Medicine, Section of Medical Oncology, and,
    • ,
  • L. Penfield Faber

      Affiliations

    • Department of Surgery, Rush University Medical Center, Chicago, IL, USA
    • ,
  • Susan Shott

      Affiliations

    • Department of Internal Medicine, Section of Medical Oncology, and,
    • ,
  • Ross A. Abrams

      Affiliations

    • Department of Radiation Oncology,
    • Department of Internal Medicine, Section of Medical Oncology, and,
    • Corresponding Author InformationCorresponding author. Dr. Ross A. Abrams, Department of Radiation Oncology, Rush University Medical Center, 1653 W. Congress Parkway, Chicago, IL 60612, USA.

Received 7 February 2006 ,Revised 30 August 2006 ,Accepted 22 September 2006.

References 

  1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin. 2005;55:10–30
  2. National Cancer Institute Surveillance, Epidemiology, and End Results Web site: Incidence, Lung and Bronchus Cancer. http://seer.cancer.gov/faststats/.
  3. Cartei G, Cartei F, Cantone A, et al. Cisplatin–cyclophosphamide–mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst. 1993;1985:794–800
  4. Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax. 2004;59:828–836
  5. Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000;592:1074–1080
  6. The elderly lung cancer vinorelbine Italian study group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;691:66–72.
  7. Schiller JH, Harrington D, Belani C, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002;346:92–98
  8. Pater JL, Loeb M. Nonanatomic prognostic factors in carcinoma of the lung: a multivariate analysis. Cancer. 1982;1550:326–331
  9. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 1980;65:25–32
  10. Twomey P, Montgomery C, Clark O, et al. Successful treatment of adrenal metastases from large-cell carcinoma of the lung. JAMA. 1982;248:581–583
  11. Iwasaki A, Shirakusa T, Yoshinaga Y, et al. Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor. Eur J Cardiothorac Surg. 2004;26:488–493
  12. Bonnette P, Puyo P, Gabriel C, et al. Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest. 2001;119:1469–1475
  13. Porte H, Siat J, Guibert B, et al. Resection of adrenal metastases from non-small cell lung cancer: a multicenter study. Ann Thorac Surg. 2001;71:981–985
  14. Porte H, Roumilhac D, Graziana J-P, et al. Adrenalectomy for a solitary adrenal metastasis from lung cancer. Ann Thorac Surg. 1998;65:331–335
  15. de Perrot M, Licker M, Robert J, et al. Long-term survival after surgical resections of bronchogenic carcinoma and adrenal metastasis. Ann Thorac Surg. 1999;1084–1085
  16. Urschel J, Finley R, Takita H, et al. Long-term survival after bilateral adrenalectomy for metastatic lung cancer: a case report. Chest. 1997;112:848–850
  17. Luketich J, Burt M. Does resection of adrenal metastases from non-small lung cancer improve survival?. Ann Thorac Surg. 1996;62:1614–1616
  18. Noordijk E, Vecht C, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys. 1994;29:711–717
  19. Patchell RA, Tibbs P, Walsh J, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500
  20. Andrews D, Scott C, Sperdullo P, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–1672
  21. Luketich J, Martini N, Ginsberg R, et al. Successful treatment of solitary extracranial metastases from non-small cell lung cancer. Ann Thorac Surg. 1995;60:1609–1611
  22. Nagashima A, Abe Y, Yamada S, et al. Long-term survival after surgical resection of liver metastasis from lung cancer. Jpn J Thorac Cardiovasc Surg. 2004;52:311–333
  23. Curran W, Scott C, Langer C, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: RTOG 9410. Proc Am Soc Clin Oncol. 2003;22;(abst)
  24. Oshita F, Ikehara M, Sekiyama A, et al. Genomewide cDNA microarray screening of genes related to benefits and toxicities of platinum-based chemotherapy in patients with advanced lung cancer. Am J Clin Oncol. 2005;28:367–370

PII: S0167-8140(06)00484-1

doi: 10.1016/j.radonc.2006.09.006

Radiotherapy & Oncology
Volume 81, Issue 2 , Pages 163-167 , November 2006

Article Tools

* Image Usage & Resolution